Company Overview

PI Industries Limited (BSE: 523642, NSE: PIIND) reported its FY26 financial and operational performance through multiple regulatory filings including Integrated Annual Report, Corporate Governance Report, Business Responsibility Report, and audited financial statements.

Financial Performance

Consolidated Results: Revenue declined 16% YoY to ₹67,137 million with EBITDA margin of 25.4%. Net profit stood at ₹13,208 million, including exceptional items of ₹1,260 million write-back partially offset by ₹229 million labor code provisions. The company maintained a strong balance sheet with net worth of ₹112,305 million (16% CAGR from FY21) and surplus net cash of ₹34,265 million.

Standalone Results: Revenue decreased 18.3% to ₹61,827 million with net profit of ₹14,348 million. The company declared interim dividend of ₹5 per share and recommended final dividend of ₹10 per share, totaling ₹2,278 million payout.

Business Segment Performance

AgChem Exports: Declined 19% YoY with volumes down ~14%, though five new molecules were commercialized and new products represented 18% of export revenues.

Domestic Business: Revenue declined ~7% YoY impacted by adverse weather, lower crop prices, and regulatory disruptions in Biologicals.

Pharma (PI Health Sciences): Grew 40% YoY to ₹3,005 million with expanded customer base from 77 to 86 and significant increase in CRO/CDMO enquiries.

Biologicals (PI AgSciences): Achieved global revenue run rate of ~USD 12 million with gross margins exceeding 60% and new regulatory approvals in India and US.

Strategic Initiatives

Pioxaniliprole Development: India's first indigenous insecticide molecule received ISO approval, with regulatory filings initiated in India and select global markets, representing shift to innovation-led company.

R&D Pipeline: Maintained 90+ molecules in active pipeline with 700+ scientists including 200+ PhDs, filed 43 patents in FY26 (cumulative 250+ granted), and built proprietary library of 80,000+ compounds.

Manufacturing Expansion: Invested ₹11,508 million capex with three new multi-product plants under construction at Jambusar and Panoli, incorporating advanced technologies.

Acquisition: Completed acquisition of PI AgSciences Limited (formerly Plant Health Care Plc) for ₹3,639 million cash, expanding biologicals portfolio.

ESG & Governance

ESG Performance: Achieved S&P Global CSA score of 77 (top 2 percentile), featured in Sustainability Yearbook 2026, with zero environmental violations, 91% waste circularity, and 21.24% renewable energy consumption.

Board Composition: 10 Directors (4 Independent, 6 Non-Independent) with key appointments including V K Viswanathan as Independent Director and Lisa J Brown as Lead Independent Director.

Management Changes: Several senior management updates including Jagresh Rana as Global Ag-CEO and Shruti Joshi as Company Secretary & Compliance Officer.

Remuneration: Executive directors received total remuneration of ₹360 million (Mayank Singhal ₹260 million, Rajnish Sarna ₹100 million).

AGM & Corporate Actions

79th Annual General Meeting: Scheduled for August 14, 2026 through video conferencing with record date of August 7, 2026 for final dividend entitlement.

Related Party Transactions: Totaled ₹2,136 million including purchases from joint venture PI Kumiai and compensation to KMPs, all at arm's length and approved by Audit Committee.

Outlook

The company maintains forward-looking statements based on current expectations while acknowledging inherent business risks and uncertainties. Continued focus on innovation, expansion, and sustainability initiatives positions PI Industries for long-term growth across agchem, pharma, and biologicals segments.